The case in front of me: retatrutide · TRIUMPH-3.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Why does this happen, and what would falsify the usual explanation?
Read TRIUMPH-3 by arm, because the arm is the unit of randomisation and every figure worth quoting is defined at that level. A programme that randomised several dose levels reports each one separately, with its own sample size and its own interval, and the pooled number that circulates afterwards describes a group nobody was assigned to. Take the primary publication and its supplementary tables rather than a summary of them: one is organised by arm, the other by whichever figure was largest. And check the estimand — what happened to everyone assigned, or what happens to those who kept taking it — because the two answer different questions and are routinely quoted as though they were one.
The glucose-dependence is the key property. Below about four millimoles per litre the insulinotropic effect largely disappears, which is why monotherapy hypoglycaemia is uncommon.
Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
It helps to be literal here: glucagon suppression is also glucose-dependent and is lost during hypoglycaemia, which preserves the counter-regulatory response — a genuinely elegant piece of physiology and the reason the class is safe in this respect.
Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.
Nausea and appetite share an anatomy, which is why they are hard to separate by dose.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the distinction between the native hormone and the pharmacological agents, whose half-lives differ by three orders of magnitude and whose effects therefore differ in kind.
Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.
More usefully, central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.
The incretin effect itself was established by comparing the insulin response to oral and intravenous glucose loads matched for plasma glucose; the difference is what the gut hormones contribute.
Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.
Start with the tissue distribution. Pancreatic islet, gastric, and several hypothalamic and brainstem populations — that list explains insulin secretion, gastric emptying and appetite in one go.
Biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.
Gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.
Structural work on the receptor by cryo-electron microscopy has resolved the agonist-bound active state and is the basis for current structure-guided design in this class.
Glucose-dependence is the property to remember; it explains the safety profile on its own.
edited 8 Mar 2025 by harriet_lonsdale — expanded the table to cover the lower concentration
This is answerable mechanistically, and the mechanism actually predicts the side-effect profile, which is unusual and worth exploiting when reasoning about it.
Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.
Nothing here is medical advice; this is pharmacology.
The half-life problem and the albumin-binding solution are the whole story of the class chemically.
The endogenous hormone is degraded by dipeptidyl peptidase-4 within a couple of minutes. Every long-acting agent in this class is essentially an answer to that one problem.
Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.
The position-8 substitution conferring DPP-4 resistance appears in essentially every long-acting agent in the class, which is about as strong a piece of convergent evidence as medicinal chemistry offers.
Mechanism is a good guide to what to expect and a poor guide to how much.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.